Hasil Pencarian - Emily Tarco

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor

    Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor oleh Santanu Adhikary, Deepavali Chakravarti, Christopher Terranova, Isha Sengupta, Mayinuer Maitituoheti, Anirban Dasgupta, Dushyant Kumar Srivastava, Junsheng Ma, Ayush T. Raman, Emily Tarco, Aysegul A. Sahin, Roland Bassett, Fei Yang, Coya Tapia, Siddhartha Roy, Kunal Rai, Chandrima Das

    Diterbitkan 2019-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

    Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. oleh Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

    Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. oleh Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

    Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation oleh Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

    Diterbitkan 2019-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: